Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients Review
| Authors: | Ranjan, S.; Leung, D.; Ghiaseddin, A. P.; Taylor, J. W.; Lobbous, M.; Dhawan, A.; Budhu, J. A.; Coffee, E.; Melnick, K.; Chowdhary, S. A.; Lu-Emerson, C.; Kurz, S. C.; Burke, J. E.; Lam, K.; Patel, M. P.; Dunbar, E. M.; Mohile, N. A.; Peters, K. B. |
| Review Title: | Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients |
| Abstract: | Management of venous thromboembolism (VTE) in patients with primary and metastatic brain tumors (BT) is challenging because of the risk of intracranial hemorrhage (ICH). There are no prospective clinical trials evaluating safety and efficacy of direct oral anticoagulants (DOACs), specifically in patients with BT, but they are widely used for VTE in this population. A group of neuro-oncology experts convened to provide practical clinical guidance for the off-label use of DOACs in treating VTE in patients with BT. We searched PubMed for the following terms: BTs, glioma, glioblastoma (GBM), brain metastasis, VTE, heparin, low-molecular-weight heparin (LWMH), DOACs, and ICH. Although prospective clinical trials are needed, the recommendations presented aim to assist clinicians in making informed decisions regarding DOACs for VTE in patients with BT. © 2024 American Cancer Society. |
| Keywords: | mortality; review; drug efficacy; drug safety; cancer patient; brain tumor; glioma; brain neoplasms; prospective study; prospective studies; neoplasm; neoplasms; melanoma; neoplasm recurrence, local; bleeding; thrombocytopenia; dexamethasone; antineoplastic activity; risk factor; histology; renal cell carcinoma; hypoalbuminemia; thromboembolism; tumor recurrence; glioblastoma; anticoagulants; warfarin; brain metastasis; heparin; papillary carcinoma; administration, oral; thyroid papillary carcinoma; brain hemorrhage; low molecular weight heparin; venous thromboembolism; anticoagulant agent; apixaban; rivaroxaban; oral drug administration; brain neoplasm; malignant glioma; cytochrome p450 3a4; complication; hemorrhage; intracranial hemorrhage; low-molecular-weight heparin; dabigatran; humans; human; edoxaban; direct oral anticoagulants; anticoagulants administration & dosage; anticoagulants adverse effects |
| Journal Title: | Cancer |
| Volume: | 130 |
| Issue: | 9 |
| ISSN: | 0008-543X |
| Publisher: | Wiley Blackwell |
| Date Published: | 2024-05-01 |
| Start Page: | 1577 |
| End Page: | 1589 |
| Language: | English |
| DOI: | 10.1002/cncr.35220 |
| PUBMED: | 38288941 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work